


**Listing of Claims:**

*This listing of claims replaces all prior versions, and listings, of claims in the captioned application.*

1. – 2. (Cancelled)

3. (Currently Amended) A compound of formula (I) according to claim 2



the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein

n is 0; X is N or CR<sup>5</sup>, wherein R<sup>5</sup> is hydrogen; R<sup>1</sup> is C<sub>1-6</sub>alkyl;

R<sup>2</sup> is hydrogen or hydroxy or taken together with R<sup>4</sup> may form =O; R<sup>3</sup> is -(CH<sub>2</sub>)<sub>8</sub>-NR<sup>6</sup>R<sup>7</sup>;

s is 0 or 1; R<sup>6</sup> is -CHO or C<sub>1-6</sub>alkyl; R<sup>7</sup> is hydrogen or C<sub>1-6</sub>alkyl;

and R<sup>4</sup> is hydrogen, C<sub>1-6</sub>alkyl -or -




4. (Currently Amended) A compound selected from the group consisting of:

<p><b>compound 1</b></p>	<p><b>compound 5</b></p>
<p><b>compound 7</b></p>	<p><b>compound 3</b></p>
<p><b>compound 17</b></p>	


and the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof.

5. – 12. (Cancelled)


13. (Currently Amended) A process for preparing a compound as claimed in claim 23, comprising: a) hydrolysis of intermediates of formula (VIII),



- b) cyclization of intermediates of formula (X),



- or c) condensation of an ortho-benzenediamine of formula (XI) with an ester of formula (XII) wherein R<sup>b</sup> is C<sub>1-6</sub>alkyl, into compounds of formula (I), wherein X is N, herein referred to as compounds of formula (I-i),



14. (Cancelled)

15. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 3.

16. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.


17. - 26. (Cancelled)

27. (Previously Presented) A combination of a compound with a cancer treating chemotherapeutic agent wherein said compound is a compound of claim 3.

28. (Previously Presented) A combination of a compound with a cancer treating chemotherapeutic agent wherein said compound is a compound of claim 4.

29. - 30. (Cancelled)

31. (Previously Presented) A compound selected from



and the *N*-oxide forms and the pharmaceutically acceptable addition salts thereof.

32. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 31.

33. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 31.